Using strict biochemical thresholds for the diagnosis of patients with suspected Cushing’s disease could help improve diagnostic accuracy, report Daniel Kelly and co-authors.
The selective glucocorticoid receptor modulator relacorilant may warrant further investigation for the treatment of endogenous Cushing’s syndrome, suggest phase 2 trial results published in Frontiers in Endocrinology in July 2021.
The 37th Congress of the Société Française d’Endocrinologie – the French Society of Endocrinology – will be held in Le Havre in October 2021.
The 2021 SfE BES is to be held at the Edinburgh International Conference Centre between 8 to 10 November 2021 with ‘on demand’ streaming services for delegates who are unable to attend in person.
Bone mineral density continues to improve for up to 20 years after treatment for Cushing’s syndrome, report Annenienke van de Ven and team.
Study findings from Martin Reincke and colleagues suggest that serum IGF-I levels 6 months after curative surgery for endogenous Cushing’s syndrome may be predictive of long-term muscle strength outcomes.